...
首页> 外文期刊>European journal of internal medicine >Reversible and non-reversible cardiovascular risk in patients treated with lipid-lowering therapy: analysis of SEAS and JUPITER trials.
【24h】

Reversible and non-reversible cardiovascular risk in patients treated with lipid-lowering therapy: analysis of SEAS and JUPITER trials.

机译:降脂治疗患者的可逆和不可逆性心血管风险:SEAS和JUPITER试验分析。

获取原文
获取原文并翻译 | 示例
           

摘要

A number of clinical trials have confirmed that statin treatment and, more generally, LDL-lowering treatment, are able to reduce CHD and CVD events in a wide range of clinical conditions associated with increased cardiovascular risk. However, the most recent trials have also identified patient groups in which lipid-lowering treatment shows a more limited preventive potential due to the non-reversibility observed treatment effect by events that are not directly a consequence of atherosclerosis. The use of lipid-lowering therapy in these patients should be driven not only by their absolute risk, as suggested by the most recent American and European guidelines, but also by their overall clinical setting and by the evidence of benefit obtained in controlled trials in comparable populations.
机译:许多临床试验已经证实,他汀类药物治疗以及更普遍地降低LDL的治疗能够在与心血管疾病风险增加相关的广泛临床条件下减少CHD和CVD事件。但是,最近的试验还确定了降脂治疗的预防潜力有限的患者组,这归因于并非由动脉粥样硬化直接导致的事件所引起的不可逆性观察到的治疗效果。在这些患者中使用降脂治疗,不仅应根据美国和欧洲最新指南的建议,确定其绝对危险,而且应根据其总体临床情况以及在可比较的对照试验中获得的益处的证据来确定。人口。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号